Company Overview
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Why Investors Should Care
Revenue has grown at a 85.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $13.00M (+85.7% YoY); net profit $-68.87M.
- Trailing 12 Months Year-on-year growth — revenue +85.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 85.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 85.71% |
| 1 Year: | 85.71% |
Stock Price Performance
| 1 Year: | -38.46% |
| 6 Months: | -41.11% |
| 3 Months: | -53.25% |
| 1 Month: | -37.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)32.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 85.7% over 5 years.
CONS
- Trading 60.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EVMN Evommune, Inc. R2K | 12.45 | -5.90 | $448.43M | 0.00% | -39.16% | -44.95% | 85.71% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | - | 3.00M | 10.00M | 0 |
| Operating Income | -16.52M | -15.03M | -13.33M | -23.95M |
| Net Income | -15.92M | -14.56M | -12.47M | -21.67M |
| Diluted EPS | -10.47 | -9.48 | -8.07 | -0.64 |
| R&D Expense | 13.29M | 14.36M | 19.64M | 17.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 7.00M | 13.00M |
| Operating Income | -70.01M | -81.07M |
| Net Income | -66.81M | -68.87M |
| Diluted EPS | -45.29 | -11.22 |
| R&D Expense | 64.24M | 74.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 76.06M | 224.95M |
| Total Equity | -77.71M | -144.24M | 205.57M |
| Cash & Equivalents | - | 16.25M | 44.06M |
| Total Liabilities | - | 28.52M | 19.38M |
| Current Liabilities | - | 27.98M | 17.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -58.20M | -76.44M |
| Investing Cash Flow | -3.99M | -115.31M |
| Financing Cash Flow | 49.42M | 220.76M |
| Capital Expenditure | -88.00K | -235.00K |
| Free Cash Flow | -58.28M | -76.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -1,000.2% | -623.6% |
| Net Margin % | -954.4% | -529.8% |
| ROE % | 46.3% | -33.5% |
| ROCE % | -145.6% | -39.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eqt Fund Management S.a R.l. | 13.69% | 4.93M | $59.11M |
| 2 | RA Capital Management, L.P. | 9.70% | 3.49M | $41.90M |
| 3 | Pivotal bioVenture Partners Investment Advisor, LLC | 5.35% | 1.93M | $23.10M |
| 4 | Andera Partners | 5.27% | 1.90M | $22.75M |
| 5 | RTW Investments LP | 4.17% | 1.50M | $18.01M |
| 6 | JPMORGAN CHASE & CO | 4.05% | 1.46M | $17.50M |
| 7 | MPM Bioimpact LLC | 4.04% | 1.46M | $17.46M |
| 8 | Nan Fung Group Holdings Limited | 4.00% | 1.44M | $17.28M |
| 9 | SymBiosis Capital Partners, LLC | 3.56% | 1.28M | $15.36M |
| 10 | Eventide Asset Management LLC | 3.36% | 1.21M | $14.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EVMN
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNN1FxTXZCeDRFWmNhVXEzR25xRGRFRTR4U0JrZU1OOFZPSWRMcm1vc0Juci1LZWZDbnhxNHhlWHdNbXVCOXBuRVdDVklubzF2MlZpakNZaHhCeDdGYk5sWFpxVXNzbGsyU1R5WUFhbEEtXzk2dmt6MDR5R3l0S3MtcHdRc1BNblR2Qkdpek…
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOOXJSLU54RnNNTFl3cDZxV2MxOWhJSTFyMUhCZmRBaWJjdE1LSjM2Z3lYRm42WDd0YjhBYUZEaUdMZG5jdVh0RUFkVXNScnJYeXA0Y1RQdDc3RWhJTFNFeC1rMS1JUTdPT19yLVpncS15cW9Zdk9NSjhyTWRhLUhYSzFwU1F5UjlnY1JfYm…
Insider Purchase: Chief Financial Officer of $EVMN Buys 1,000 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbjFnczh0bFN5bkxrcmU2NUp6eTZsMGFiejJxcWNnRDRGZjJhV25URjhzbjIxd2Jmd3VRQUN5dm1YbzgxR0hGS2tDTkxsVllFOUc3TTAwMDhjOXVJTENBOW5pWENhSGE0Zzd3LTFWcmFncDJkQjl0MF9ELS1lVGpPZ3J3VzNpYmt0bmlpVn…
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNc3g4bFQ2czdQSVd1eXR4Zkl2NDg4YXRDdVAwbkRpVDE3ME5SY09YV3ZRTDQzMDAyaFhNWVM1XzlPdFpWTlVMRWYwalFHZEFxS1ozSEM2NjBMM2lVRWZmbGtac0ViNUc4bnNnTGFxOVczdnlySV82VmJ1SzFrU0plNUhQM09nU25ScXRqUz…
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZHpnaVphUFZ0U2xndmlnVTdPYmpmY3lfdmNwUjZtcF8xM0JvdWpEa04zSEVnNnNwdVhwalFNYl9QTlpBbC1VYUtJT0xSRldwTGtYUGJicjFtenBIVlIzOG02UGJkRmx4S2tNNGYwX05zMHhGMmpLTGJyRDdHSVRkT1ZveHV5a0c4VzJ2bF…
Evommune director Arthur Kirsch buys $133,000 of EVMN stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOaGtPZkE2X2VDTlQ1SllwNXp6U3A3MmZXOFV5Q3FtbkpPMDRPNzZ5bDV0OEJVUHl5MDZCSDN3d2NUNDRqNG5taGZfQjhKLVdsR3BYTEJTSnZocWlmOWpSTWxNWWc0a3F1SjZmbnVTXzZ5cDFJTEpXN3F4YUk5S3NLVmZwaDRKdGFGcDlfeG…
EVMN — Frequently Asked Questions
What is the current share price of Evommune, Inc. (EVMN)?
As of 2026-07-15 16:51 PDT, Evommune, Inc. (EVMN) trades at $12.45 on NYSE. Its 52-week range is $11.99 to $31.57.
What is the market capitalisation of EVMN?
Evommune, Inc. (EVMN) has a market capitalisation of $448.43M on NYSE.
What is the P/E ratio of EVMN?
EVMN trades at a trailing price-to-earnings (P/E) ratio of -5.90. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.42.
What is the return on equity (ROE) of EVMN?
EVMN has a return on equity (ROE) of -44.95%. Its return on capital employed (ROCE) is -39.16%.
Is EVMN a good stock to buy?
This page provides a data-driven analysis of Evommune, Inc. (EVMN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.